Edgewise Therapeutics, Inc.

EWTX · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumVery strong
SafetyBalanced

Overall confidence 39/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Very high (46/100) · Gap confidence 57/100Documented progress is running well ahead of market attention.

This month at a glance

AIR Score™ change: 0AIR Score™ held steady this month.

Cycle window9 Sep 2026 → 10 Sep 2026

MoversNothing moved meaningfully this month.

Evidence timeline

[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 6, 2026 · FORM 8-K
[8-K 2.01] Edgewise Therapeutics, Inc. — Completion of Acquisition or Disposition of AssetsSEC · SEC EDGAR
Jul 10, 2026 · FORM 8-K
[8-K 1.01] Edgewise Therapeutics, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
May 31, 2026 · 8-K
[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 7, 2026 · FORM 8-K
[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Feb 26, 2026 · FORM 8-K
[8-K 5.02] Edgewise Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Nov 19, 2025 · FORM 8-K
[8-K 5.02] Edgewise Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
Nov 10, 2025 · FORM 8-K
[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Nov 6, 2025 · FORM 8-K
[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 7, 2025 · FORM 8-K
[8-K 8.01] Edgewise Therapeutics, Inc. — Other EventsSEC · SEC EDGAR
Jun 26, 2025 · FORM 8-K
[8-K 2.02] Edgewise Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 8, 2025 · FORM 8-K
[8-K 1.01] Edgewise Therapeutics, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Apr 2, 2025 · FORM 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.